Femasys (FEMY) Competitors $0.88 -0.05 (-5.33%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$0.89 +0.01 (+0.75%) As of 07:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock FEMY vs. SLNO, MBOT, ICAD, ZJYL, FONR, APYX, VANI, NTRB, GUTS, and SRTSShould you be buying Femasys stock or one of its competitors? The main competitors of Femasys include Soleno Therapeutics (SLNO), Microbot Medical (MBOT), icad (ICAD), Jin Medical International (ZJYL), Fonar (FONR), Apyx Medical (APYX), Vivani Medical (VANI), Nutriband (NTRB), Fractyl Health (GUTS), and Sensus Healthcare (SRTS). These companies are all part of the "medical equipment" industry. Femasys vs. Its Competitors Soleno Therapeutics Microbot Medical icad Jin Medical International Fonar Apyx Medical Vivani Medical Nutriband Fractyl Health Sensus Healthcare Femasys (NASDAQ:FEMY) and Soleno Therapeutics (NASDAQ:SLNO) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership. Do insiders and institutionals have more ownership in FEMY or SLNO? 65.3% of Femasys shares are held by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are held by institutional investors. 11.5% of Femasys shares are held by insiders. Comparatively, 6.4% of Soleno Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media favor FEMY or SLNO? In the previous week, Soleno Therapeutics had 12 more articles in the media than Femasys. MarketBeat recorded 13 mentions for Soleno Therapeutics and 1 mentions for Femasys. Soleno Therapeutics' average media sentiment score of 0.96 beat Femasys' score of 0.00 indicating that Soleno Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Femasys 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Soleno Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, FEMY or SLNO? Femasys has a beta of -2.58, meaning that its stock price is 358% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -2.56, meaning that its stock price is 356% less volatile than the S&P 500. Do analysts rate FEMY or SLNO? Femasys presently has a consensus target price of $8.67, suggesting a potential upside of 882.17%. Soleno Therapeutics has a consensus target price of $113.30, suggesting a potential upside of 43.95%. Given Femasys' higher possible upside, analysts clearly believe Femasys is more favorable than Soleno Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 Is FEMY or SLNO more profitable? Soleno Therapeutics has a net margin of 0.00% compared to Femasys' net margin of -1,242.06%. Soleno Therapeutics' return on equity of -73.21% beat Femasys' return on equity.Company Net Margins Return on Equity Return on Assets Femasys-1,242.06% -392.45% -137.15% Soleno Therapeutics N/A -73.21%-57.44% Which has higher valuation and earnings, FEMY or SLNO? Femasys has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFemasys$1.70M16.89-$18.82M-$0.91-0.97Soleno TherapeuticsN/AN/A-$175.85M-$4.62-17.04 SummarySoleno Therapeutics beats Femasys on 10 of the 16 factors compared between the two stocks. Get Femasys News Delivered to You Automatically Sign up to receive the latest news and ratings for FEMY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FEMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FEMY vs. The Competition Export to ExcelMetricFemasysMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.32M$2.98B$5.48B$9.57BDividend YieldN/A2.46%3.99%4.17%P/E Ratio-0.9717.9729.9425.14Price / Sales16.89262.51398.9486.71Price / CashN/A41.8335.9458.58Price / Book8.827.238.105.59Net Income-$18.82M-$54.43M$3.26B$265.48M7 Day Performance7.66%0.22%0.68%1.22%1 Month Performance-4.09%5.59%2.46%0.39%1 Year Performance2.59%9.98%27.69%23.47% Femasys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FEMYFemasys2.8184 of 5 stars$0.88-5.3%$8.67+882.2%-16.0%$30.32M$1.70M-0.9730Upcoming EarningsSLNOSoleno Therapeutics4.5817 of 5 stars$85.25-1.4%$108.70+27.5%+79.0%$4.36BN/A-18.4530Earnings ReportAnalyst ForecastGap UpMBOTMicrobot Medical1.6608 of 5 stars$2.90-2.4%$9.00+210.3%+204.9%$108.04MN/A-4.4620Upcoming EarningsGap UpHigh Trading VolumeICADicadN/A$3.87flatN/AN/A$106.31M$19.61M-20.37140Upcoming EarningsZJYLJin Medical InternationalN/A$0.66+2.0%N/A-78.7%$101.54M$23.50M0.00245FONRFonar1.4919 of 5 stars$15.96-0.7%N/A-5.4%$99.69M$102.88M12.77480APYXApyx Medical1.1007 of 5 stars$2.42-4.7%N/A+94.1%$96M$48.10M-4.40270News CoverageEarnings ReportVANIVivani Medical2.814 of 5 stars$1.60-0.6%$4.00+150.0%+17.2%$95.38MN/A-3.7220Positive NewsUpcoming EarningsNTRBNutriband2.7368 of 5 stars$8.07-5.4%$13.00+61.1%+35.0%$95.14M$2.14M-8.9710Positive NewsGUTSFractyl Health2.5675 of 5 stars$1.97+2.6%$11.00+458.4%-49.9%$94.04M$90K-1.06102Upcoming EarningsSRTSSensus Healthcare1.9228 of 5 stars$5.32-3.4%$11.67+119.3%-9.6%$90.61M$41.81M53.2040Earnings Report Related Companies and Tools Related Companies Soleno Therapeutics Alternatives Microbot Medical Alternatives icad Alternatives Jin Medical International Alternatives Fonar Alternatives Apyx Medical Alternatives Vivani Medical Alternatives Nutriband Alternatives Fractyl Health Alternatives Sensus Healthcare Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FEMY) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Femasys Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Femasys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
